Adult Dosing
Chemotherapy related hyperuricemia
- 0.2 mg/kg IV infusion 30 minutes q24 hrs for up to 5 days
- Safety and efficacy >5 days and >1 course is not established
Pediatric Dosing
Hyperurecemia
- 0.2 mg/kg IV infusion 30 minutes q 24 hrs for up to 5 days
- Safety and efficacy >5 days and >1 course is not established
[Outline]
- Immediately and permanently discontinue rasburicase if clinically serious hypersensitivity reaction including anaphylaxis occurs [U.S. Black Box Warning]
- Immediately and permanently discontinue in patients with hemolysis; prior to therapy screen patients at risk of G6PD deficiency (e.g. patients of African or Mediterranean ancestry) [U.S. Black Box Warning]
- Immediately and permanently discontinue the drug if methemoglobinemia occurs, institute proper monitoring and supportive treatment [U.S. Black Box Warning]
- At room temperature, enzymatic degradation of uric acid takes place in blood/plasma/serum sample, to avoid collect the sample in pre-chilled tubes containing heparin, immediately immerse and maintain in an ice water and assay sample within 4 hrs of collection [U.S. Black Box Warning]
- Monitor closely for hypersensitivity and atopic allergies
Cautions: Use cautiously in
- G6PD deficiency risk factors
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer recommends discontinuation of nursing or discontinuation of therapy, by analyzing risk and benefit ratio in nursing mothers.
